Table of Contents

01 - Consultee response – Gilead Sciences

02 - Consultee response – Haemophilia Society

03 - Consultee response – The Hepatitis C Trust

04 - Consultee response – Study of the Liver (BASL) and the British Viral Hepatitis Group (BVHG)

05 - Consultee response – British HIV Association (BHIVA)

06 - Consultee response – British Society of Gastroenterology (BSG)

07 - Consultee response – Royal College of Physicians

08 - Consultee response – NHS England

09 - Consultee response – NHS England and Hepatitis C CRG subgroup

10 - Consultee response – Janssen

11 - Consultee response – Roche Products

12 – ACD comments received through the NICE website

13 – Clinical expert response from Cramp and patient expert response from Gore

14 – Evidence Review Group critique of analyses submitted by Gilead Sciences

15 – Clarification from the European Marketing Authorisation (EMA) on the marketing authorisation of ledipasvir-sofosbuvir

16 – Company response to NICE clarification request

17 – Supplementary data and analyses submitted by Gilead Sciences

18 - Consensus Meeting Report on HCV Treatment

19 – Evidence Review Group critique of Company’s additional analyses

20 – NICE clarification questions to NHS England on Hep C drugs

21 – NHS England clarification response

22 – Consultee response – Gilead Sciences

23 – Consultee response – The Hepatitis C Trust

24 – Consultee response – British HIV Association (BHIVA) and the British Association of Sexual Health and HIV (BASHH)

25 – Consultee response – British Society of Gastroenterology (BSG), British Viral Hepatitis

Group (BVHG), British Association for the Study of Liver (BVHG) and Royal College of Pathologists

26 – Consultee response – Royal College of Physicians

27– Consultee response – United Kingdom Clinical Pharmacy Association (UKCPA)

28 – Consultee response – Foundation for Liver Research

29 – Clinical expert response from Cramp

30 – Patient expert response from Gore

31 – Public health expert response from Harris